Cargando…

PD‐1/PD‐L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway

OBJECTIVES: Although targeted therapy has revolutionized the treatment of gastrointestinal stromal tumours (GIST), it is almost never curative in GIST, and resistance commonly develops. One potential strategy is to combine targeted therapy with immunotherapy. MATERIALS AND METHODS: We first studied...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Rui, Song, Yinghan, Wang, Yong, Huang, Yuqian, Li, Zhigui, Cui, Yaping, Yi, Mengshi, Xia, Lin, Zhuang, Wen, Wu, Xiaoting, Zhou, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536456/ https://www.ncbi.nlm.nih.gov/pubmed/30714229 http://dx.doi.org/10.1111/cpr.12571

Ejemplares similares

M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
por: Zhao, Rui, et al.
Publicado: (2020)

Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
por: Freeman, Gordon J., et al.
Publicado: (2006)

Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
por: Esfahani, Khashayar, et al.
Publicado: (2019)

mTOR regulates T cell exhaustion and PD-1–targeted immunotherapy response during chronic viral infection
por: Ando, Satomi, et al.
Publicado: (2023)

Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion
por: Alvarez, Maite, et al.
Publicado: (2020)

Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor
por: Bai, Xin, et al.
Publicado: (2021)

Searching for the real function of mTOR signaling in the regulation of PD-L1 expression
por: Sun, Shi-Yong
Publicado: (2020)

PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells
por: Viramontes, Karla M., et al.
Publicado: (2022)

PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1(hi)CD39(+) CD4 T cells
por: Balança, Camille-Charlotte, et al.
Publicado: (2021)

The identification of TCF1(+) progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade
por: Tabanelli, Valentina, et al.
Publicado: (2022)

Circulating Exhausted PD-1(+)CD39(+) Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade
por: Martinez-Gomez, Carlos, et al.
Publicado: (2022)

PD-L1 dimerisation induced by biphenyl derivatives mediates anti-breast cancer activity via the non-immune PD-L1–AKT–mTOR/Bcl2 pathway
por: Zhang, Hua, et al.
Publicado: (2023)

Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells
por: Dong, Ling, et al.
Publicado: (2016)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
por: Zhong, Mengjun, et al.
Publicado: (2022)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

PD-1 Blockade Modulates Functional Activities of Exhausted-Like T Cell in Patients With Cutaneous Leishmaniasis
por: Garcia de Moura, Renan, et al.
Publicado: (2021)

Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation
por: Roberts, Alexander, et al.
Publicado: (2021)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer
por: Quan, Zihan, et al.
Publicado: (2022)

A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway
por: Zhao, Lei, et al.
Publicado: (2017)

CD40 Activation Rescues Antiviral CD8(+) T Cells from PD-1-Mediated Exhaustion
por: Isogawa, Masanori, et al.
Publicado: (2013)

Correction to: BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
por: Zhong, Mengjun, et al.
Publicado: (2022)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
por: Katsuya, Hiroo, et al.
Publicado: (2023)

PD-L1 Status in Gastric Cancers, Association with the Transcriptional, Growth Factors, AKT/mTOR Components Change, and Autophagy Initiation
por: Spirina, Liudmila, et al.
Publicado: (2021)

MM-129 as a Novel Inhibitor Targeting PI3K/AKT/mTOR and PD-L1 in Colorectal Cancer
por: Hermanowicz, Justyna Magdalena, et al.
Publicado: (2021)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

Correction: CD40 Activation Rescues Antiviral CD8(+) T Cells from PD-1-Mediated Exhaustion
por: Isogawa, Masanori, et al.
Publicado: (2016)

Correction: CD40 Activation Rescues Antiviral CD8(+) T Cells from PD-1-Mediated Exhaustion
por: Isogawa, Masanori, et al.
Publicado: (2017)

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
por: Skalniak, Lukasz, et al.
Publicado: (2017)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o30bdkhoeer8f714kla2ni6kj7